News Sentiment

MBX sentiment intelligence

MBX Biosciences, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 62.92 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+3.1% over one week, +46.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

MBX Biosciences (NASDAQ:MBX) Rating Lowered to "Sell" at Wall Street Zen

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 3.1% Price confirming higher
Trend fit Trend active 46.2% over four weeks
Fair value 179.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 29
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
MarketBeat 7
TradingView 6
Investing.com 3
simplywall.st 3
Stock Titan 2
TIKR.com 2
Barron's 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 17
Analyst action 6
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
MarketBeat Direct company coverage

MBX Biosciences (NASDAQ:MBX) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen has downgraded MBX Biosciences (NASDAQ:MBX) from a "hold" to a "sell" rating, despite other analysts like Barclays, Truist Financial, and Citizens JMP recently increasing their price targets. The stock currently holds a "Moderate Buy" consensus rating with a $63.0

Tone
Negative 40/100
Event
Analyst action
Published
20 Jul 2026 05:11
Source
MarketBeat
MarketBeat Direct company coverage

MBX Biosciences (NASDAQ:MBX) Trading 5.1% Higher - What's Next?

MBX Biosciences (NASDAQ:MBX) shares increased by 5.1% on Friday, trading as high as $60.11 and closing at $61.30, despite a significant drop in trading volume. Analysts maintain a generally positive outlook, with a consensus "Moderate Buy" rating and an average price target of $6

Tone
Positive 66/100
Event
Analyst action
Published
17 Jul 2026 17:11
Source
MarketBeat
Sahm Direct company coverage

Is MBX Biosciences (MBX) Fairly Valued As New Leadership Takes Charge?

MBX Biosciences (MBX) has appointed Steve Hoerter as CEO and Chairman and John Smither as CFO, following a significant surge in its stock price. The article examines the company's valuation using the price-to-book ratio, noting it appears expensive compared to the broader pharmac

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 09:11
Source
Sahm
The Globe and Mail Direct company coverage

MBX Biosciences Announces CEO Transition and Leadership Updates

MBX Biosciences announced a leadership transition, with CEO Kent P. Hawryluk stepping down on July 13, 2026. Steven Hoerter has been named the new President, CEO, and principal executive officer, while John Smither is confirmed as CFO. The company's stock currently holds a "Buy"

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 09:09
Source
The Globe and Mail
MarketBeat Direct company coverage

MBX Biosciences (NASDAQ:MBX) Shares Gap Down - Should You Sell?

MBX Biosciences (NASDAQ:MBX) experienced a gap down at market open, falling from $60.04 to $52.82 before trading at $55.83. Despite the dip, analysts generally maintain a "Moderate Buy" consensus with an average price target of $60.22, though one analyst still recommends selling.

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 15:42
Source
MarketBeat
Minichart Direct company coverage

MBX Biosciences Appoints New CEO and CFO: Leadership Changes Announced in July 2026 8-K Filing

MBX Biosciences, Inc. (NASDAQ: MBX) has announced significant executive leadership changes detailed in a recent Form 8-K filing. Kent P. Hawryluk will step down as CEO, with Steven Hoerter appointed as the new President and CEO, and John Smither named permanent CFO, all effective

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 01:12
Source
Minichart
Investing.com Direct company coverage

MBX Biosciences names Steve Hoerter as CEO, Kent Hawryluk steps down

MBX Biosciences has appointed Steve Hoerter as its new Chairman and CEO, succeeding co-founder Kent Hawryluk. The company also named John Smither as its permanent CFO. This leadership change comes as MBX Biosciences' stock has surged 368% over the past year, and the company is pr

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:12
Source
Investing.com
Stock Titan Direct company coverage

MBX Biosciences (Nasdaq: MBX) names new CEO and CFO, sets pay and equity

MBX Biosciences has announced significant leadership changes, with Kent P. Hawryluk stepping down as CEO and director, effective July 13, 2026. Steven Hoerter, previously executive chairman, has been appointed as the new President and CEO, while interim CFO John Smither has been

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:12
Source
Stock Titan
Investing.com Direct company coverage

MBX Biosciences stock falls on CEO and CFO leadership changes

MBX Biosciences Inc. (NASDAQ:MBX) shares dropped 8.3% after announcements of executive leadership changes. Steve Hoerter, currently Executive Chairman, was appointed new Chairman and CEO, replacing Kent Hawryluk. John Smither, who served as Interim CFO, was made permanent Chief F

Tone
Negative 29/100
Event
Market update
Published
13 Jul 2026 16:34
Source
Investing.com
TradingView Direct company coverage

Enterprise value to EBIT forward of MBX Biosciences, Inc. – NASDAQ:MBX

This article provides financial data for MBX Biosciences, Inc. (NASDAQ:MBX), specifically its enterprise value to EBIT forward. It indicates that the market was closed at the time of publication and gives an overview of the company's financial information available on TradingView

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 09:10
Source
TradingView
MarketBeat Direct company coverage

Candriam S.C.A. Purchases New Holdings in MBX Biosciences, Inc. $MBX

Candriam S.C.A. has initiated a new position in MBX Biosciences, acquiring 294,374 shares valued at approximately $8.79 million during the first quarter. This move, representing 0.62% of MBX Biosciences, aligns with increased interest from other institutional investors like Welli

Tone
Positive 65/100
Event
Earnings
Published
13 Jul 2026 08:10
Source
MarketBeat
TradingView Direct company coverage

Price to sales forward of MBX Biosciences, Inc. – NASDAQ:MBX

The article references the "Price to sales forward" metric for MBX Biosciences, Inc. (NASDAQ:MBX) on TradingView. It provides contextual information about accessing financial data for the company within the TradingView platform. The content is very brief, mainly serving as a navi

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 00:09
Source
TradingView
MarketBeat Direct company coverage

MBX Biosciences (NASDAQ:MBX) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded MBX Biosciences (NASDAQ:MBX) from a "sell" to a "hold" rating. This comes amidst other analyst ratings ranging from "Strong Buy" to "Sell," with a consensus of "Moderate Buy" and an average price target of $60.22. The article also notes recent stock p

Tone
Positive 65/100
Event
Analyst action
Published
12 Jul 2026 17:40
Source
MarketBeat
MarketBeat Direct company coverage

MBX Biosciences (NASDAQ:MBX) Trading Down 6.9% - Time to Sell?

MBX Biosciences (NASDAQ:MBX) shares dropped 6.9% on Friday, trading at $61.17 after closing at $65.71 the previous day, with significantly lower trading volume. Analyst opinions are mixed but lean towards "Moderate Buy" with a consensus price target of $60.22, despite some recent

Tone
Negative 36/100
Event
Analyst action
Published
10 Jul 2026 16:41
Source
MarketBeat
Stock Titan Direct company coverage

Wellington Group discloses 4.98M-share stake in MBX Biosciences (MBX)

Wellington Management Group LLP and its affiliates have disclosed a beneficial ownership of 4,977,523 shares, or 10.46%, in MBX Biosciences common stock through a Schedule 13G/A filing. These shares are held in client accounts, with shared voting and dispositive powers across var

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 16:59
Source
Stock Titan
Investing.com Direct company coverage

MBX Biosciences stock hits all-time high at 59.55 USD

MBX Biosciences Inc. (MBX) stock reached an all-time high of $59.55, trading near its 52-week high, reflecting a significant market capitalization of $2.75 billion and a 352.03% increase over the past year. This growth is attributed to investor confidence and positive company dev

Tone
Positive 92/100
Event
Market update
Published
08 Jul 2026 07:09
Source
Investing.com
TradingView Direct company coverage

Enterprise value to revenue forward of MBX Biosciences, Inc. – NASDAQ:MBX

This article focuses on the enterprise value to revenue forward metric for MBX Biosciences, Inc. (NASDAQ:MBX). It appears to be a financial data page from TradingView, providing an overview of various financial aspects and tools available for analyzing the company's stock.

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 01:41
Source
TradingView
Investing.com UK Direct company coverage

MBX Biosciences stock hits all-time high at 59.55 USD By Investing.com

MBX Biosciences Inc. (MBX) stock reached an all-time high of $59.55, trading within 1% of its 52-week high, bringing its market capitalization to $2.75 billion. This surge reflects a 352.03% increase over the past year, driven by investor confidence and positive developments, inc

Tone
Positive 95/100
Event
Market update
Published
07 Jul 2026 16:30
Source
Investing.com UK